Virna Cortez-Retamozo

Virna Cortez-Retamozo

Company: Sanofi

Job title: Senior Principal Scientist

Seminars:

Industry-Focused Panel Discussion 5:00 pm

During development of new immuno-modulatory therapeutics, when is the best time to evaluate cytokine release? Options include: As a stand-alone assay comparing molecules in a side-by-side assay for lead selection During analysis of preclinical efficacy as part of the overall mode of action Later stage, post preclinical efficacy to determine safety/tox prior to IND filing.Read more

day: Day One

Discussion/Q&A 2:25 pm

Read more

day: Day One

Improved Antitumor Activity of Local immunotherapy with mRNA Encoding Cytokines and Immune Checkpoint Blockade in Multiple Preclinical Syngeneic Tumor models with “Cold” and “Hot” Immune Phenotype 1:50 pm

Anti-tumor activity of intratumoral cytokine mRNA therapy in combination with immune check blockade in 12 syngeneic mouse models with “cold” and “hot” immune phenotypes Immune mediated mechanism of action of combination therapy with cytokine mRNA and anti-PD-1 antibodyRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.